Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM4ZBK6)

Drug Name
Fedratinib Drug Info
Synonyms TG101348
Indication
Disease Entry ICD 11 Status REF
Myelofibrosis 2A20.2 Approved [1]
Polycythemia vera 2A20.4 Approved [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Investigative [3]
Cross-matching ID
PubChem CID
16722836
ChEBI ID
CHEBI:91408
CAS Number
CAS 936091-26-8
TTD Drug ID
DM4ZBK6
ACDINA Drug ID
D01069

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Janus kinase 2 (JAK-2) TTRMX3V JAK2_HUMAN Inhibitor [1]
HUMAN janus kinase 2 (JAK-2) TT0F5HE JAK2_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Janus kinase 2 (JAK-2) DTT JAK2 4.957 5.257 4.986 4.784
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Myelofibrosis
ICD Disease Classification 2A20.2
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Janus kinase 2 (JAK-2) DTT JAK2 2.46E-01 -0.41 -0.6
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 212327
3 TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7.